Novartis Partners With Clinton Foundation, Indian And Chinese Drug Makers To Improve Access To Malaria Drugs
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Novartis and the Clinton Foundation have entered into agreements with six Indian and Chinese companies with the objective of lowering the price of malaria drugs and thereby improving access for patients in the developing and underdeveloped world
You may also be interested in...
SinoBiomed To Conduct Clinical Trials In Thailand For China’s First Malaria Vaccine
SHANGHAI - SinoBiomed will conduct Phase IIb clinical trials of its recombinant malaria vaccine in Thailand in cooperation with Bangkok-based Mahidol University, the company announced Aug. 20
SinoBiomed To Conduct Clinical Trials In Thailand For China’s First Malaria Vaccine
SHANGHAI - SinoBiomed will conduct Phase IIb clinical trials of its recombinant malaria vaccine in Thailand in cooperation with Bangkok-based Mahidol University, the company announced Aug. 20
Novartis’ Paul Herrling And En Li On R&D Strategy In China, India And The Pacific Rim: An Interview With PharmAsia News (Part 2 of 2)
[Editor's Note: This is part two of a two-part interview. Part one appeared May 4, 2008 in PharmAsia News.]